PeproMene Bio Overview
- Year Founded
-
1913
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
6
- Investments
-
1
PeproMene Bio General Information
Description
Developer of immunotherapy products designed to treat cancers and immune disorders. The company's technology targets B-cell activating factor receptors, addresses CD19-resistant models, utilizes novel antibody technology, treats relapsed B-cell malignancies, provides durable complete responses, and overcomes tumor antigen loss, providing healthcare providers with treatments for patients with unmet medical needs.
Contact Information
Website
www.pepromenebio.comCorporate Office
- 15375 Barranca Parkway
- Suite A211
- Irvine, CA 92618
- United States
Corporate Office
- 15375 Barranca Parkway
- Suite A211
- Irvine, CA 92618
- United States
PeproMene Bio Timeline
PeproMene Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PeproMene Bio Signals
PeproMene Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PeproMene Bio Investments (1)
PeproMene Bio’s most recent deal was a PIPE with Binex (Busan) for . The deal was made on 21-Mar-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Binex (Busan) | 21-Mar-2018 | PIPE | Other Pharmaceuticals and Biotechnology |
PeproMene Bio FAQs
-
When was PeproMene Bio founded?
PeproMene Bio was founded in 1913.
-
Where is PeproMene Bio headquartered?
PeproMene Bio is headquartered in Irvine, CA.
-
What is the size of PeproMene Bio?
PeproMene Bio has 7 total employees.
-
What industry is PeproMene Bio in?
PeproMene Bio’s primary industry is Drug Discovery.
-
Is PeproMene Bio a private or public company?
PeproMene Bio is a Private company.
-
What is PeproMene Bio’s current revenue?
The current revenue for PeproMene Bio is .
-
How much funding has PeproMene Bio raised over time?
PeproMene Bio has raised $50.2M.
-
Who are PeproMene Bio’s investors?
Institute for Follicular Lymphoma Innovation, KB Investment, Seven Tree Equity Partners, Binex (Busan), and Solidus Investment have invested in PeproMene Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process